Hematology

Long-term follow-up shows ravulizumab effective in paroxysmal nocturnal hemoglobinuria

In this study, 441 patients from 2 pivotal phase 3 studies comparing ravulizumab to eculizumab in complement inhibitor-naïve (n = 301) and complement inhibitor-experienced (n = 302) patients with paroxysmal nocturnal hemoglobinuria after 26 weeks of treatment, continued treatment with ravulizumab throughout the extension period. During the extension period, improvements...